Damien Paul, Lanham Holly J, Parthasarathy Murali, Shah Nikhil L
McCombs School of Business, University of Texas in Austin, Austin, USA.
The University of Texas Health Science Center San Antonio, San Antonio, USA.
BMC Health Serv Res. 2016 Dec 28;16(1):690. doi: 10.1186/s12913-016-1922-4.
To examine key factors influencing chronic kidney disease (CKD) patients' total expenditure and offer recommendations on how to reduce total cost of CKD care without compromising quality.
Using the 2002-2011 Medical Expenditure Panel Survey (MEPS) data, our cross-sectional study analyzed 197 patient records-79 patients with one record and 59 with two entries per patient (138 unique patients). We used three patient groups, based on international statistical classification of diseases version 9 code for condition (ICD9CODX) classification, to focus inference from the analysis: (a) non-dialysis dependent CKD, (b) dialysis and (c) transplant. Covariate information included region, demographic, co-morbid conditions and types of services. We used descriptive methods and multivariate generalized linear models to understand the impact of cost drivers. We compared actual and predicted CKD cost of care data using a hold-out sample of nine, randomly selected patients to validate the models.
Total costs were significantly affected by treatment type, with dialysis being significantly higher than non-dialysis and transplant groups. Costs were highest in the West region of the U.S. Average costs for patients with public insurance were significantly higher than patients with private insurance (p < .0743), and likewise, for patients with co-morbid conditions over those without co-morbid conditions (p < .001).
Managing CKD patients both before and after the onset of dialysis treatment and managing co-morbid conditions in individuals with CKD are potential sources of substantial cost savings in the care of CKD patients. Comparing total costs pre and post the United States Affordable Care Act could provide invaluable insights into managing the cost-quality tradeoff in CKD care.
研究影响慢性肾脏病(CKD)患者总支出的关键因素,并就如何在不影响质量的前提下降低CKD护理总成本提供建议。
利用2002 - 2011年医疗支出面板调查(MEPS)数据,我们的横断面研究分析了197份患者记录——79名患者有一份记录,59名患者每人有两份记录(共138名不同患者)。根据国际疾病分类第9版病情编码(ICD9CODX)分类,我们将患者分为三组,以便在分析中聚焦推断:(a)非透析依赖型CKD,(b)透析组,以及(c)移植组。协变量信息包括地区、人口统计学特征、合并症情况和服务类型。我们使用描述性方法和多元广义线性模型来了解成本驱动因素的影响。我们使用随机选择的9名患者的留存样本比较CKD实际护理成本和预测护理成本数据,以验证模型。
总费用受治疗类型的显著影响,透析组的费用显著高于非透析组和移植组。美国西部地区的费用最高。公共保险患者的平均费用显著高于私人保险患者(p < 0.0743),同样,有合并症患者的费用高于无合并症患者(p < 0.001)。
在透析治疗开始前后管理CKD患者以及管理CKD患者的合并症,是在CKD患者护理中大幅节省成本的潜在来源。比较美国《平价医疗法案》实施前后的总成本,可为管理CKD护理中的成本 - 质量权衡提供宝贵见解。